Advertisement

Advertisement
Leukemia
Survivorship

Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL

In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...

Lung Cancer

Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC

In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...

Breast Cancer
Gastroesophageal Cancer
Gastrointestinal Cancer

FDA Approves Trastuzumab Biosimilar Trastuzumab-strf

The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...


Advertisement
Gynecologic Cancers

FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...

Breast Cancer

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...

Advertisement
Advertisement




Sponsored Content


Lung Cancer

Narjust Florez, MD, and Ticiana Leal, MD, on Metastatic NSCLC: Tumor Treating Fields Therapy After Platinum Resistance

Lung Cancer
Genomics/Genetics

FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC

First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

CNS Cancers

Lisa M. DeAngelis, MD, and Ingo K. Mellinghoff, MD, on Glioma: Phase III Results on Vorasidenib

Breast Cancer

Circulating Leukocyte Subsets After Breast Cancer Diagnosis and Treatment

In an analysis reported in JAMA Network Open, Jacob K. Kresovich, PhD, and colleagues identified differences in circulating leukocyte subsets between women who were diagnosed and treated for breast cancer vs those not diagnosed with breast cancer. As stated by the investigators: “Changes in...

Issues in Oncology
Cost of Care

Preferred Sites of Cancer Care: Community Oncology Practices vs Hospitals and Academic Centers

Investigators uncovered that community oncology practices emerged as the preferred sites of service for cancer treatment compared with hospitals and academic centers, according to a recent case study. The findings may challenge the common perception of hospitals and academic centers as preferable...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Colorectal Cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Leukemia

Blinatumomab as an Alternative to First-Line Intensive Chemotherapy in Pediatric B-Cell ALL

In a retrospective study reported in the Journal of Clinical Oncology, Hodder et al found that blinatumomab was effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons with B-cell acute lymphoblastic leukemia (ALL) who were...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter